792 followers
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma https://t.co/KVmqkryPHB
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma https://t.co/KVmqkryPHB
MAP17 Predicts Sensitivity to Platinum-Based Therapy, EGFR Inhibitors & the Proteasome Inhibitor Bortezomib in Lung Adenocarcinoma @sloan_kettering https://t.co/ZF3skCKAU7 https://t.co/0Dqc7AqpWr